🇺🇸 FDA
Pipeline program

Kesimpta 20 mg solution for injection in pre-filled syringe

COMB157G2410

Approved small_molecule active

Quick answer

Kesimpta 20 mg solution for injection in pre-filled syringe for Relapsing forms of Multiple Sclerosis (RMS) is a Approved program (small_molecule) at Novartis Ophthalmics Europe with 1 ClinicalTrials.gov record(s).

Program details

Company
Novartis Ophthalmics Europe
Indication
Relapsing forms of Multiple Sclerosis (RMS)
Phase
Approved
Modality
small_molecule
Status
active

Clinical trials